noted that mice with diminished CASP3 expression exhibited reduced anti‐tumour immunity,53 elucidating, from another perspective, why patients with high‐risk NSCLC demonstrate enhanced immune responses (Figure 8C). This evidence concerns the gene CASP3 and non-small cell lung carcinoma.